This study aimed to prepare core–shell structural PLGA nanoparticles of astaxanthin (ASTA-PLGA@M) via micelle template for sustained release in vitro and long-term hepatoprotective effects in vivo. The morphology, mean particle size, zeta potential, polydispersity index (PDI), and drug loading efficiency of optimized formulation were investigated. Meanwhile, the physicochemical characterizations including X-ray diffraction (XRD) and attenuated total reflectance-Fourier transform infrared (ATR-FTIR) of ASTA-PLGA@M were evaluated to prove the successful encapsulation of astaxanthin. The in vitro release of astaxanthin from ASTA-PLGA@M in four different media was sustained slowly for 120 h. An in vivo release study also demonstrated that ASTA-PLGA@M nanoparticles enhanced oral bioavailability significantly. In addition, the hepatoprotective effects of astaxanthin on oxidative stress (OS) accompanied by apoptosis in acute hepatic damage caused by carbon tetrachloride (CCl4) in mice were investigated. ASTA-PLGA@M nanoparticles provide a clear elevating effect on the activity of SOD and inhibit the increase of MDA during acute liver damage caused by CCl4. Moreover, histopathological analysis was conducted to study the long-term hepatoprotective effects of ASTA-PLGA@M for further application of astaxanthin in functional food or clinical use.